Phase III
Shares dropped by 9.1 percent, the biggest intraday decline since June 2016.
Alzheimer’s drug development took another hit.
A look at three drug approvals of vital importance to the company this year.
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Late-stage data shows the use of Pfizer’s prostate cancer drug Xtandi plus ADT significantly reduced the risk of developing metastases or death by 71 percent.
Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.
A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31.
BMS shares climb more than 4% this morning after the company announced its anticipated Phase III CheckMate-227 study data.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy.
PRESS RELEASES